Dr. Melissa Reed -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Melissa Reed, a Internal Medicine physician based in Ann Arbor, MI. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Melissa Reed has received $117,258.16 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Melissa Reed
- Medical Specialty: Internal Medicine
- Practice Location: Ann Arbor, MI, Michigan
- NPI Number: 1031646942
- Transparency Score: 50/100
- Payment Records Span: 2024-11-28 to 2024-11-28
Payment Summary
Dr. Melissa Reed has received a total of $117,258.16 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $117,258.16 per transaction.
- Total Payments Received: $117,258.16
- Number of Transactions: 1
- Average Payment: $117,258.16
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Melissa Reed's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Ownership Interest | $117,258.16 | Ownership stakes, dividends, and investment returns |
The largest payment category for Dr. Melissa Reed is Ownership Interest, accounting for 100% ($117,258.16) of total pharmaceutical payments received. This indicates a financial ownership interest in a pharmaceutical or medical device company.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Melissa Reed. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Pfizer Inc | $117,258.16 | 1 |
Dr. Melissa Reed has a financial relationship with Pfizer Inc, receiving $117,258.16 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Melissa Reed. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Eliquis -- Referenced in payment records from pharmaceutical companies to Dr. Melissa Reed
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Melissa Reed's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Melissa Reed, an Internal Medicine specialist in Ann Arbor, MI, has a pharmaceutical payment profile characterized by a single, substantial payment totaling $117,258.16. This payment, received on November 28, 2024, from Pfizer Inc., is specifically categorized as 'ownership.' When compared to the typical payment landscape for Internal Medicine physicians, this profile is highly unusual. The average Internal Medicine doctor may receive multiple smaller payments throughout the year for various activities such as consulting, speaking engagements, meals, travel, or research. A single, large payment designated as 'ownership' stands out significantly. This suggests a potential equity stake or investment in Pfizer Inc., rather than routine compensation for services like consulting or speaking. While ownership interests can be a legitimate form of compensation or investment, a payment of this magnitude from a single pharmaceutical company warrants careful consideration. It raises questions about potential conflicts of interest, as a financial stake in a company could theoretically influence prescribing decisions towards that company's products. However, it is crucial to note that ownership does not automatically equate to biased practice. Many physicians may have legitimate investments that do not impact their clinical judgment. For patients, understanding these relationships is part of informed healthcare. While this payment is a significant outlier, it doesn't inherently mean Dr. Reed's care is compromised. Patients should engage in open communication with their physician about treatment options and the rationale behind prescribing choices. The transparency of such financial relationships allows patients to be more informed consumers of healthcare.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Melissa Reed is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's financial relationships with pharmaceutical companies, it's important to maintain perspective. Most doctors receive some form of payment, which can be for legitimate activities like research, consulting, or speaking, helping to advance medical knowledge. However, a single, large payment, particularly for 'ownership' as seen with Dr. Reed and Pfizer Inc., is an outlier and might prompt further inquiry. At your next appointment, consider asking your doctor about their relationships with pharmaceutical companies and how these might inform their treatment recommendations. You could ask, 'Are there any financial relationships you have with drug companies that might influence the medications we discuss?' Red flags might include a doctor exclusively prescribing medications from a company they receive substantial payments from, or if they seem overly dismissive of alternative treatments. Normal relationships often involve smaller, diverse payments for educational activities. Concerning relationships might involve large, exclusive payments from a single company, especially for ownership stakes. Evaluate your doctor's prescribing patterns by comparing their choices to general guidelines or by discussing alternatives with them. Remember, transparency is key, and open communication can help build trust.
Peer Comparison: How Dr. Melissa Reed Compares to Other Internal Medicine Physicians
Dr. Reed's total payment of $117,258.16 from a single source is exceptionally high and deviates significantly from the typical payment profile for Internal Medicine physicians. While many Internal Medicine doctors receive payments for various services, the average annual total is often in the low thousands, spread across multiple companies and payment types. A single payment of this magnitude, especially for 'ownership,' is not representative of the peer group, suggesting a unique financial relationship rather than common professional engagement.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Melissa Reed in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Pfizer Inc | $117,258.16 | ownership | Eliquis | 2024-11-28 | Not Assessed |
Frequently Asked Questions About Dr. Melissa Reed's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Melissa Reed taking too much pharma money?
Dr. Reed received a single payment of $117,258.16 for 'ownership' from Pfizer Inc. This is a substantial amount and a highly unusual payment type for the average Internal Medicine physician, who typically receives smaller, more frequent payments for services like consulting or speaking. While this single large payment for ownership is an outlier, it does not automatically indicate that Dr. Reed is prescribing inappropriately. It does, however, represent a significant financial tie that patients may wish to be aware of.
What pharma companies pay Dr. Melissa Reed?
Dr. Melissa Reed received a total of $117,258.16 from one pharmaceutical company: Pfizer Inc. This entire amount was associated with an 'ownership' payment.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a personal decision. While Dr. Reed's single, large 'ownership' payment from Pfizer Inc. is unusual, it doesn't automatically mean her care is compromised. Consider the overall quality of care you receive, your trust in your doctor, and their communication style. If you have concerns, discuss them openly with Dr. Reed. If you remain uncomfortable or feel your concerns are not addressed, seeking a second opinion or a new physician is always an option.
What kinds of payments does this doctor receive?
Dr. Reed received one payment totaling $117,258.16, which was specifically categorized as 'ownership' from Pfizer Inc. She has not received payments categorized as consulting, speaking, meals, travel, or research.
How do these payments compare to other Internal Medicine?
Dr. Reed's payment profile is highly atypical for Internal Medicine. The average physician in this specialty receives payments that are significantly lower in total amount and are usually distributed across multiple companies and payment types (e.g., consulting, speaking, meals). Her single, large 'ownership' payment is an outlier compared to the routine professional activities that typically generate payments for her peers.
Do pharma payments affect prescribing quality?
Research suggests that even small payments from pharmaceutical companies can influence physician prescribing habits, often subtly. Larger payments, especially those indicating ownership or significant consulting roles, may carry a greater potential for bias. However, many physicians maintain ethical practices despite financial ties. The key is transparency and critical evaluation of prescribing patterns in conjunction with known financial relationships.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for 'Dr. Melissa Reed' and her National Provider Identifier (NPI) number '1031646942'. The database provides detailed records of payments made by pharmaceutical and medical device companies to physicians and teaching hospitals.
Understanding This Doctor Payment Report
This transparency report for Dr. Melissa Reed is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Melissa Reed's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Melissa Reed and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- Michigan Physician Payments -- Browse pharmaceutical payments to physicians in Michigan
- Internal Medicine Physicians in Michigan -- Compare Dr. Melissa Reed to peers in the same state and specialty
- Pfizer Inc Payment Profile -- View all payments made by Dr. Melissa Reed's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Melissa Reed's NPI (1031646942) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.